A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder

Project Information

SAGAPROPLUS

Grant agreement ID: 782075

DOI

10.3030/782075

Project closed

EC signature date 9 August 2017

Start date 1 August 2017

End date 30 November 2017

Funded under

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

SAGAMEDICA - HEILSUJURTIR EHF
Iceland

Periodic Reporting for period 1 - SAGAPROPLUS (A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder)

Reporting period: 2017-08-01 to 2017-11-30

Summary of the context and overall objectives of the project

Over active bladder (OAB) is an age-related syndrome, more frequent in adults +65. It is extremely common, affecting ~500 million people and expected to keep rising due to aging of developed societies. OAB represents a human and economical burden for which no good solutions are available. OAB treatment has two lines of intervention: i) changes in lifestyle (diet, Kegel exercises) that are only partially effective and dependent on patients’ commitment, and ii) pharmacological treatment (anticholinergic drugs that inhibit contraction of bladder muscles), only partially effective and associated with multiple side effects, resulting in extremely high drop-out rates.
SagaMedica has identified the need for better treatments for OAB and has developed SagaPro+, a natural solution for dealing with OAB symptoms. SagaPro+ is made from leaves of plant Angelica Archangelica, and offers unique properties for OAB management: i) efficiency: SagaPro+ has been validated in OAB patients who reported an improvement of their symptoms, ii) safety: no side effects have been observed, iii) natural origin: SagaPro+ is 100% natural and consists only of Angelica extracts, and iv) sustainability: its harvesting and manufacturing processes have been kept local, sustainable and eco-friendly.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We have performed a study to confirm viability of SAGAPRO+: i) technically we designed a large-scale clinical trial and defined the requirements for industrialization, ii) commercially we investigated the regulatory pathway for SagaPro+, as well as carried out a detailed study of OAB market, and iii) financially, we updated our business plan and confirmed project’s profitability.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Economic impact: SagaPro+’s affordable price will alleviate both direct and indirect costs of OAB management to the healthcare system. Societal impact: a natural solution like SagaPro+ will alleviate the symptoms without side effects improving the quality of life of affected patients allowing them to have a normal everyday life.

image-2.png

image-1.png